Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03829436
Title TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tempest Therapeutics
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.